Objective: To evaluate the clinical efficacy and safety of the DDGP regimen in treating extranodal NK/T-cell lymphoma and investigate the correlation between Epstein-Barr virus (EBV)-DNA variation after treatment and the clinical efficacy of NK/T-cell lymphoma. Methods: Sixty-four patients with extranodal NK/T-cell lymphoma received DDGP regimen-based chemotherapy. Short-term and long-term clinical efficacy and adverse reactions were observed. The relationship between EBV-DNA changes before and after therapy and clinical efficacy was investigated. Results: After the DDGP regimen was used as the initial treatment, the short-term clinical efficacy included 39 complete remission (CR) (60.94%), 12 partial remission (PR) (18.75%), 2 stable disease (SD) (3.13%) and 11 progressive disease (PD) (17.18%). Objective response rate (ORR) was 79.69% and 82.82% for disease control rate (DCR). 3-year progression-free survival (PFS) was 62.00% and 3-year overall survive (OS) was 74.90%. Hemocytopenia was the predominant adverse effect. Between EBV-DNA positive group and its negative counterpart, a significant difference was noted in OS (P=0.046), but no difference in ORR, DCR or PFS was observed. In the EBV-DNA positive group, ORR, DCR, PFS and OS were higher for patients whose EBV-DNA copy number decreased within a normal range than patients remained positive (93.33% versus 61.53%, P=0.041 for ORR; 93.33% versus 61.53%, P=0.041 for DCR, P=0.003 for PFS, P=0.017 for OS). The main adverse reactions included bone marrow suppression, gastrointestinal reaction and coagulation dysfunction, which were mitigated and treated after expectant or dose-decrement treatment. Conclusion: DDGP regimen can significantly improve the clinical prognosis of NK/T-cell lymphoma patients with tolerable adverse reactions. The variation in EBV-DNA is correlated with clinical efficacy and prognosis, which provides a theoretical basis for NK/T-cell lymphoma therapy.
Introduction
Extranodal natural killer/T-cell lymphoma (nasal type, ENKTL) is a relatively rare type of malignant lymphoma that is highly malignant.
1 Nasal cavity-type ENKTL originates from the nasal cavity with a predilection for the nasal septum and inferior nasal concha. Common nasal diseases include nasal tumors, nasal obstruction and nosebleeds. Along with the progression of diseases, patients present with nasal space-occupying lesions, extensive involvement with adjacent soft tissues, ulcers and bone destruction. [2] [3] [4] Extranasal-type ENKTL affects the skin, gastrointestinal tract and reproductive organs with diverse manifestations according to the different organs involved. A clinical trial is recommended for the treatment of NK/T-cell lymphoma. The treatment for these patients mainly includes chemotherapy, radiotherapy or hematopoietic stem-cell transplantation. Better efficacy for radiotherapy was observed in early stage but poor efficacy in the advanced stage. In recent years, checkpoint inhibitors have been explored as a novel therapeutic approach by enhancing antitumor immunity by blocking immune check points with antibodies, a pathway that has been shown to be increasingly important in ENKTL. PD-1/PD-L1 are responsible for this negative immune regulation and are the targets of the antitumor effect. 5, 6 However, effective first-line treatment of NK/T-cell lymphoma remains to be explored. In the earliest, anthracycline-containing chemotherapy regimens, such as CHOP, were the mainstay of advanced ENKTL treatment. However, as P-glycoprotein in lymphoma cells, which leads to drug efflux and resistance to treatment, these regimens yield poor outcomes. 7, 8 To explore more effective chemotherapy regimens for ENKTL, a series of studies on ENKTL therapy have been carried out since 2009 in the Lymphoma Diagnosis and Treatment Center, Henan, China. The IC50 values of 30 types of chemotherapy agents (such as anthracycline, vincristine, breviscapine, dacarbazine, cisplatin, methotrexate, gemcitabine, colaspase and pegaspargase) on the NK/T-cell lymphoma cell line SNK-6 were detected in vitro to identify the medications with low IC50 values, high sensitivity, different action sites and no overlapping side effects. 9 The DDGP chemotherapy regimen alone (cisplatin, dexamethasone, gemcitabine and pegaspargase) was applied to treat advanced NK/T-cell lymphoma. a pivotal parameter for the assessment of the clinical prognosis of NK/T-cell lymphoma patients. Nevertheless, the relationship between the dynamic variation in copy number of EBV-DNA and clinical prognosis during the treatment of ENKTL has been rarely investigated. In this study, EBV-DNA variation before and after the DDGP regimen was studied to investigate the relationship between EBV and the clinical efficacy and prognosis of NK/T-cell lymphoma.
Materials and methods

General data
Sixty-four patients with advanced stage NK/T-cell lymphoma admitted to the First Affiliated Hospital of Zhengzhou University between March 2011 and April 2018 were recruited in this clinical trial. The diagnosis of ENKTL was validated by more than two experienced professors from the Department of Pathology.
Patients with no medical history of chemotherapy or radiotherapy received 4-6 cycles of the DDGP regimen as the initial treatment. The clinical characteristics of all patients are illustrated in Table 1 . 
Clinical treatment
Evaluation criteria
Imaging methods to evaluate the efficacy of all patients included CT or PET-CT, if necessary we usually combined with color doppler ultrasound and MRI. The clinical efficacy was assessed according to the WHO evaluation criteria as the complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). 13 The Quantification ofEBV-DNA A 5 mL patient peripheral blood was obtained, sent to the PCR laboratory (The First Affiliated Hospital of Zhengzhou University), then separate the plasma sample. Amplification was performed according to the instructions of EBV nucleic acid amplification fluorescence quantitative detection kit (Da An Gene Co., Ltd. of Sun Yat-sen University, Guangzhou, China). The amplification result with less than 5.00E + 02 copies/mL is defined as negative for EBV-DNA. More than 5.00E + 02 copies/mL is defined as positive for EBV-DNA. (31/36) in the EBV-DNA-negative group, with no significant difference (P=0.428). In the EBV-DNA-positive group, the copy number of EBV-DNA decreased within normal range included 15 cases after the DDGP regimen. The negative conversion ratio was 53.57% (15/28) . The ORR of the negative group was 93.33% (14/15), which significantly differed from 61.53% (8/13) for the positive group (P=0.041), and the DCR was the same.
Long-termclinical efficacy
The final date of follow-upwas in April 2018. The median follow-upwas 40 months. Among the 64 ENKTL patients, 15 died. Nine patients died of disease progression, 2 patients died of cerebral hemorrhage, 2 patients died of gastrointestinal hemorrhage, 1 patient died of multiple organ failure, and 1 patient died of unknown causes. Six patients presenting with disease progression and 3 released patients were switched to an alternative regimen and were subsequently excluded from this clinical trial. Among them 3 patients were positive for EBV and 6 patients were negative for EBV. Finally, the OS of 55 patients was assessed. The 1-, 2-and 3-year PFS was 77.00%, 67.80% and 62.00%, respectively, and the 1-, 2-and 3-year OS was 81.50% 74.9% and 74.90%, respectively, as illustrated in Figure 1A and B. In the EBV-DNApositive group, the 1-, 2-and 3-year PFS was 70.30%, 67.50% and 67.50%, respectively. In the EBV-DNAnegative group, the 1-, 2-and 3-year PFS was 79.90%, 68.80% and 58.6%, respectively. No significant difference was noted in PFS between the two groups (P=0.812). In the EBV-DNA-positive group, the 1-, 2-and 3-year OS was 73.75%, 62.6% and 62.60%, respectively. In the EBV-DNA-negative group, the 1-, 2-and 3-year OS was 89.90%, 85.4% and 85.40%, respectively. A significant difference was noted in OS between the two groups (P=0.046), as illustrated in Figure 2A and B. In the EBV-DNA-positive group, the 1-year PFS of the negative group was 90.90%, which was significantly higher than that (43.1%) in the positive group (P=0.003). Moreover, the 1-year OS was 93.30% and 44.90% in the negative and positive groups, respectively, which were significantly different (P=0.017), as illustrated in Figure 3A and B.
Adverse reactions
Adverse reactions mainly included bone marrow suppression, digestive tract reactions, coagulation dysfunction, etc. Among the 64 patients, 48.4% presented with grade III-IV leukopenia; 62.5%, with grade I-II anemia; 42.2%, with grade III-IV thrombocytopenia; 65.6%, with digestive tract reactions; and 37.5%, with slight coagulation dysfunction, as illustrated in Table 2 .
Discussion
The prevalence of ENKTL is relatively low, and ENKTL is rarely seen in clinical practice. Few case-control studies have been conducted. At present, no standard treatment or principles have been established. serve as a remedy and consolidate therapy after chemotherapy for patients with advanced-stage ENKTL. 19 Gemcitabine is a novel type of cytidine derivative. It is a deoxycytidine analog and a new difluorine nucleotide anti-metabolism anticancer drug. Gemcitabine is a cell cycle-specific agent. 20 Gemcitabine functions by eliminating the cells at the S phase and blocking the cell proliferation from the G1 phase to the S phase. Active metabolites of diphosphate and triphosphate difluorine deoxycytidine insert into the DNA of tumor cells, leading to the interruption of DNA synthesis and cellular apoptosis. This agent exerts a broad-spectrum antitumor effect and plays a synergistic role in combination with platinum, vindesine and hormone medications. 21 In vitro experiments also revealed that gemcitabine possesses favorable membrane penetrability and strong affinity for deoxycytidine kinase and is retained within the cells for a long time, suggesting that it has relatively high antitumor activity. Relevant investigations have been carried out in our center. 9, 22 in which the IC50 values of different chemotherapy agents upon the NK/T-cell lymphoma SNK-6 cell line are studied. The results demonstrate that gemcitabine (0.002 μg/mL) has the lowest IC50 value and acts in a time-and dosedependent manner. [23] [24] [25] Currently, a pegaspargase-based chemotherapy regimen is recommended as the first-line treatment for patients with middle-and advanced-stage and refractory recurrent ENKTL according to the NCCN guidelines. Asparagine is an essential amino acid for protein synthesis. Normal cells in the human body can not only uptake asparagine from the blood circulation but also synthesize asparagine via asparagine synthetase. However, tumor cells can only uptake exogenous asparagine due to the lack of asparagine synthetase. 26 Pegaspargase is able to hydrolyze asparagine in the blood into aspartic acid and ammonia. Thus, tumor cells without asparagine synthetase lack an essential amino acid, which inhibits the synthesis of DNA, RNA and protein, blocks the exogenous source of asparagine for tumor cells and suppresses the synthesis of protein.
Consequently, pegaspargase exerts an antitumor effect. 27, 28 Nagafuji et al 29 first reported that patients for whom ENKTL recurred after autologous peripheral blood stem cell transplantation obtained partial response after the administration of L-asparagine (L-ASP) and were still surviving during an 18-month follow-up. Due to relatively severe allergic reactions, L-ASP is rarely utilized in clinical practice. 30 L-ASP functions via a distinct mechanism with explicit clinical efficacy. However, due to the relatively short half-life of L-ASP, it should be administered multiple times to maintain the required drug concentration. Along with the increasing frequency of medicine administration, the incidence of allergic reactions is elevated accordingly. Hence, the use of L-ASP is strictly restricted in clinical settings. As a novel type of asparagine enzyme preparation, pegaspargase integrates polyethylene glycol into the nonactive site of L-ASP to form a macromolecular vector medication with a t1/2 of 4-6 times higher than that of colaspase. Consequently, it is more convenient to utilize and possesses longer action times in clinical practice compared with colaspas. 10, 31, 32 Due to its low immunogenicity, it is safe to use pegaspargase wieth a low incidence of allergic reactions. It is applicable for patients who are allergic to colaspase. In the present study, to resolve the potential allergic reactions of kidrolase, a large dose of hormone was supplemented to decrease the formation of kidrolase antibody, thereby reducing the incidence of allergic reactions. Moreover, the hormone can also eliminate lymph tumor cells. 33, 34 The findings in this study demonstrate that the DDGP regimen (cisplatin, dexamethasone, gemcitabine and pegaspargase) is efficacious for ENKTL patients. 33, 34 In fact, our center had conducted a study to compare the clinical efficacy of DDGP regimen and SMILE regimen in 2016. The result showed that DDGP chemotherapy resulted in significant improvement in PFS, OS and better tolerability compared with SMILE chemotherapy for newly diagnosed advanced NK/T cell lymphoma patients. 34 In addition, we collect the reports on the treatment regimen of gemcitabine or/and L-asparaginase for NK/T cell lymphoma in recent years and Table 3 summarizes the latest published results. [35] [36] [37] [38] Quantitative detection of serum EBV-DNA found that in 53.57% of patients with positive EBV-DNA turn negative for EBV-DNA after DDGP treatment. The ORR and DCR in the EBV-DNA-positive group were 79.69% (22/28) and 79.69% (22/28) , and those in the EBV-DNA-negative group were 80.56% (29/36) and 86.11% (31/36), respectively. In the EBV-positive group, the ORR and DCR were both 93.3% (14/15) for patients who turned negative for EBV and 61.53% (8/13) for those who remained positive for EBV. A significant difference was observed in the ORR and DCR between patients positive and negative for EBV. This indicated that the patients with advanced NK/T-cell lymphoma achieved good therapeutic effects after the DDGP regimen. However, a refractory high copy number of EBV is an unfavorable factor affecting the therapeutic effect. In the EBV-positive group, the 1-, 2-and 3-year PFS was 70.30%, 67.50% and 67.50%, respectively. In the EBV-negative group, the 1-, 2-and 3-year PFS was 79.9%, 68.80% and 58.6%, respectively. In the EBV-positive group, the 1-, 2-and 3-year OS was 73.57%, 62.6% and 62.60%, respectively. In the EBV-negative group, the 1-, 2-and 3-year OS was 89.9%, Abbreviations: ORR, overall response rate; CR, complete remission; OS, overall survival; PFS, progression-free survival; DDGP, cisplatin, dexamethasone, gemcitabine and pegaspargase; RT, radiotherapy; y, year; P-gemox, pegaspargase, gemcitabine and oxaliplatin; SMILE, dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide; AspaMetDex, L-asparaginase, methotrexate, and dexamethasone.
58.4% and 85.4%, respectively. There was a significant difference in OS (P=0.046), but no significant difference was noted in the PFS (P=0.812) between the two groups, possibly because of the small sample size. However, the PFS values in the EBV-negative group were higher than those in the EBVpositive group. In the EBV-positive group, the 1-year PFS and 1-year OS in patients negative for EBV were 90.9% and 93.3%, respectively, and 43.1% and 44.9%, respectively, in those positive for EBV. Kumai et al also found that the copy number in over half of patients positive for EBV was negative after treatment, 39 prompting the possibility of inhibiting the copy number of plasma EBV-DNA through anti-virus therapy or alternative methods or performing prognosis stratification analysis and establishing individualized therapeutic regimens according to the dynamic detection of the EBV-DNA copy number before, during and after the therapy, thereby improving the clinical prognosis of ENKTL patients. In this study, the overall ORR was 79.69%, the overall DCR was 82.82%, the 1-, 2-and 3-year PFS was 77.00%, 67.80% and 58.6%, respectively, and the 1-, 2-and 3-year OS was 81.50%, 74.9% and 74.90%, respectively, after the DDGP regimen. The main adverse events included bone marrow suppression, often manifested as leukopenia, slight anemia and thrombocytopenia. The administration of granulocyte colony stimulating factor, recombinant human thrombopoietin or interleukin-11 was recommended as the expectant treatment. Preventive anti-infection therapy and platelet infusion were also necessary. The dose of chemotherapy agent was reduced by 20% in the next cycle of chemotherapy upon the appearance of grade IV adverse events. In addition, 65.6% of patients presented with digestive tract reaction, 35.9% of patients with liver function injury and 37.5% of patients with mild coagulation dysfunction. No patients showed allergic reactions. In addition to the regular detection of liver function and coagulation functions, fresh frozen plasma, cryoprecipitate or human fibrinogen should be administered in a timely manner to treat the hypofibrinogenemia induced throughout the therapy. Moreover, corresponding measures should be taken to protect the liver and stomach from vomiting. During subsequent follow-up, no patient died from adverse reactions. Taken together, this prospective study demonstrates that the DDGP regimen (cisplatin, dexamethasone, gemcitabine and pegaspargase) yields relatively high efficacy in the treatment of ENKTL, which can effectively minimize the tumor size, mitigate relevant symptoms and induce few adverse reactions with excellent tolerance. Nevertheless, the sample size is small, and the follow-up duration is short. Consequently, long-term clinical trials with larger sample sizes are urgently required. Currently, we are still recruiting more patients in our center to more accurately evaluate the clinical efficacy and safety of the DDGP regimen. Along with the rapid development of immune inhibitors, chemotherapy in combination with checkpoint inhibitors enhances the clinical efficacy in treating lymphoa. 40 Hence, this regimen combined with checkpoint inhibitors is currently a promising treatment direction. More clinical trials are urgently required to validate the results. The good prognosis of the copy number of EBV-DNA declined within normal range in the positive group also reminded anti-EBV therapy may be an effective treatment for NK/T cell lymphoma. Currently, EB-virsus targeted immunotherapy is under development, we look forward to its arrival and bring another breakthrough in the treatment of lymphoma.
Conclusion
Our study demonstrated that the DDGP regimen can significantly improve the clinical prognosis of NK/T-cell lymphoma patients with tolerable adverse reactions. The EBV-DNA variation is correlated with clinical efficacy and prognosis, which provides a theoretical basis for NK/T-cell lymphoma therapy.
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